An Open-Label, Phase 1b, Multi-Arm Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Patients With Advanced Melanoma
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 22
- 试验地点
- 14
- 主要终点
- Number of Dose Limiting Toxicities (DLTs) During the Dose-escalation Safety Lead-in Phase
研究概览
简要总结
The purpose of this study is to determine the initial safety profile and initial antitumor activity of the combination treatments (immune checkpoint inhibitors [nivolumab, ipilimumab] with investigational drugs [TAK-580, TAK-202 (plozalizumab), vedolizumab]) in the 3 arms when administered to participants with advanced melanoma.
详细描述
The drugs being tested in this study are called TAK-580, TAK-202 (plozalizumab), and vedolizumab. These investigational drugs were given along with standard of care checkpoint inhibitors ([nivolumab in Arms 1 and 2] or nivolumab + ipilimumab in Arm 3). This study looked at the safety profile of the combination treatments in each arm when administered to participants with metastatic melanoma.
The study planned to enroll approximately 156 participants. Participants were assigned to one of the 3 treatment groups:
- TAK-580 + nivolumab
- TAK-202 (plozalizumab) + nivolumab
- vedolizumab + nivolumab + ipilimumab
This study consists of 3 parts. A dose-escalation safety lead-in phase, confirmatory safety phase and a cohort expansion phase. This multi-center trial will be conducted in the United States. The overall time to participate in this study is 50 weeks. Participants may make multiple visits to the clinic and 30, 60, and 90 days after last dose of study drug for follow-up assessments.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Is a male or female participant of 18 years or older.
- •Has histologically confirmed, unresectable Stage III or Stage IV melanoma per the American Joint Committee on Cancer (AJCC) staging system.
- •Has an eastern cooperative oncology group (ECOG) performance status of 0-
- •Adequate bone marrow reserve and renal and hepatic function within 28 days before the first dose of study drug on the basis of the defined laboratory parameters.
- •For TAK-580 + nivolumab and TAK-202 (plozalizumab) + nivolumab only: Had disease accessible for repeat nonsignificant risk biopsy (those occurring outside the brain, lung/mediastinum, and pancreas, or obtained with endoscopic procedures extending beyond the esophagus, stomach, or bowel) and willingness to undergo serial tumor biopsies.
- •Additional Inclusion Requirements for TAK-580 + nivolumab
- •a) BRAF V600 mutation-positive or NRAS mutation-positive disease previously untreated with RAF, MEK, or other inhibitors of the mitogen-activated protein kinase (MAPK) pathway. Participants who have progressed on these agents can still be enrolled in TAK-202 (plozalizumab) + nivolumab or vedolizumab + nivolumab + ipilimumab.
- •Additional Inclusion Requirements for expansion cohorts only a) Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (Version 1.1) and at least 1 nonsignificant risk, non-target lesion accessible for biopsy per the guidelines above (for TAK-580 + nivolumab and TAK-202 (plozalizumab) + nivolumab only).
排除标准
- •Has active brain metastases or leptomeningeal metastases. Participants with brain metastases are eligible if these have been treated and there is no magnetic resonance imaging (MRI) evidence of progression for at least 4 weeks after treatment is complete and within 28 days prior to first dose of study drug administration. There must also be no requirement for high doses of systemic corticosteroids that could result in immunosuppression (greater than [>] 10 milligram per day [mg/day] prednisone equivalents) for at least 2 weeks prior to study drug administration.
- •Completed a prior therapy less than (<) 2 weeks prior to first dose and for whom adverse events (AEs) related to prior therapy had not returned to baseline or improved to Grade
- •Has active, known or suspected autoimmune disease.
- •Has a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of study drug administration.
- •Has a history of pneumonitis requiring treatment with steroids; history of idiopathic pulmonary fibrosis (including pneumonitis), interstitial lung disease, drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest computed tomography (CT) scan; history of radiation pneumonitis in the radiation field (fibrosis) is permitted.
- •Is previously diagnosed human immunodeficiency virus (HIV) infection or active hepatitis B or C.
- •Additional Exclusion Requirements for arm 1 only (nivolumab Plus TAK-580)
- •Concomitant use or administration of clinically significant enzyme inducers less than or equal to (<=) 14 days before the first dose of TAK-
- •Treatment with gemfibrozil (or other strong CYP2C8 inhibitor) within 14 days before the first dose of TAK-
- •Left ventricular ejection fraction (LVEF) <50 percent (%) as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 4 weeks before receiving the first dose of study drug.
- •Known gastrointestinal (GI) disease or prior GI procedure that could interfere with the oral absorption or tolerance of the TAK-
- •Additional Exclusion Requirements for arm 3 only (vedolizumab Plus nivolumab Plus ipilimumab)
- •Had prior exposure to rituximab, natalizumab, vedolizumab, or alemtuzumab.
- •Has a history of any major neurological disorders, including stroke, multiple sclerosis, or neurodegenerative disease.
- •Has taken any live vaccinations within 30 days before study drug administration except for the influenza vaccine.
研究组 & 干预措施
TAK-580 + nivolumab
TAK-580 orally, once weekly along with nivolumab, intravenous, every 2 weeks.
干预措施: TAK-580 (Drug)
TAK-580 + nivolumab
TAK-580 orally, once weekly along with nivolumab, intravenous, every 2 weeks.
干预措施: nivolumab (Drug)
TAK-202 (plozalizumab) + nivolumab
TAK-202 (plozalizumab) 2 milligram (mg), intravenous, once in Week 1, 3, 5, 9, and every 4 weeks thereafter with nivolumab infusion, intravenous, every 2 weeks.
干预措施: TAK-202 (Drug)
TAK-202 (plozalizumab) + nivolumab
TAK-202 (plozalizumab) 2 milligram (mg), intravenous, once in Week 1, 3, 5, 9, and every 4 weeks thereafter with nivolumab infusion, intravenous, every 2 weeks.
干预措施: nivolumab (Drug)
vedolizumab + nivolumab + ipilimumab
Vedolizumab intravenous, once in Week 1, 3, 5, and 13 along with nivolumab infusion, intravenous, once in Week 1, 4, 7, 10, and 13 and every 2 weeks thereafter, along with ipilimumab intravenous, once in Week 1, 4, 7, and 10.
干预措施: vedolizumab (Drug)
vedolizumab + nivolumab + ipilimumab
Vedolizumab intravenous, once in Week 1, 3, 5, and 13 along with nivolumab infusion, intravenous, once in Week 1, 4, 7, 10, and 13 and every 2 weeks thereafter, along with ipilimumab intravenous, once in Week 1, 4, 7, and 10.
干预措施: nivolumab (Drug)
vedolizumab + nivolumab + ipilimumab
Vedolizumab intravenous, once in Week 1, 3, 5, and 13 along with nivolumab infusion, intravenous, once in Week 1, 4, 7, 10, and 13 and every 2 weeks thereafter, along with ipilimumab intravenous, once in Week 1, 4, 7, and 10.
干预措施: ipilimumab (Drug)
结局指标
主要结局
Number of Dose Limiting Toxicities (DLTs) During the Dose-escalation Safety Lead-in Phase
时间窗: TAK-580 + Nivolumab and TAK-202 + Nivolumab: Baseline up to Week 9; Vedolizumab + Nivolumab + Ipilimumab: Baseline up to Week 7
DLTs was evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.
次要结局
- Overall Response Rate (ORR) During the Dose-escalation Safety Lead-in Phase(Baseline up to Week 50)
- Progression-free Survival (PFS) During the Dose-escalation Safety Lead-in Phase(From first dose date to the date of the first documentation of confirmed PD or death (up to Week 50))
- Overall Survival (OS) During the Dose-escalation Safety Lead-in Phase(From first dose of study drug until date of death from any cause (up to Week 50))
- Duration of Response (DOR) During the Dose-escalation Safety Lead-in Phase(From date of first documented confirmed CR/PR until date of first documentation of PD or death (up to Week 50))
- Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)(From the first dose of study drug up to 30 days after the last dose of study drug (up to Week 50))